The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

Higher incidence of Simian virus 40 in primary gastric diffuse large B cell lymphoma (DLBCL) than primary nodal disease in Chinese patients, but of no prognostic implication.

Print

Sub-category:
Lymphoma

Category:
Adult Leukemia, Lymphoma and Transplantation

Meeting:
2004 ASCO Annual Meeting

Abstract No:
6671

Citation:
Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 6671

Author(s):
R. Liang, S. Y. Ma; University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region of China

Abstract:

Background: Studies have reported the detection of simian polyomavirus SV40 DNA sequence in 10-40% of non-Hodgkin’s lymphoma patients and there is compelling evidence that SV40 may contribute to the oncogenesis in human. However, its incidence in Chinese patients, prognostic implication and site predilection are largely unknown. Methods: We analysed the diagnostic histological specimens from 49 Chinese patients with diffuse large B cell lymphoma diagnosed from 1989 to 1996. PCR followed by Southern blot hybridization were performed and SV 40 specific DNA was confirmed by DNA sequencing. Results: Among the 49 patients (M:F=28:21; mean age=58 years ,range 22-83), there were 7 cases (14%) positive for SV 40 by PCR and 6 of them were confirmed to be SV 40 specific DNA, giving an incidence of 12%. Primary sites were peripheral lymph node (n=30, 61%), gastric (n=18, 37%) and sternal soft tissue (n=1, 2%). Primary gastric lymphoma had a significantly higher SV40 positivity rate than the nodal disease (5/18, 28% versus 1/30, 3.3%; p=0.02) There was no difference between the SV40 positive and SV 40 negative patients in terms of mean age (51 versus 59), IPI score (2.5 versus 1.9), LDH level (565 versus 675), no. of chemotherapy regimens (6.17 versus 6.3) and first complete remission (CR) rate (67% versus 58%). With a median follow up of 3 years, 31 (63%) patients died (4/6 in SV40 positive versus 27/43 in negative, p=not significant). The overall median survival was 51 months with no difference between SV40 positive and negative cases (53 versus 39 months). Conclusions: SV40 was found at low incidence rate of 12% in Chinese DLBCL patients and it had no prognostic values. However, there was a significant association with gastric lymphoma. Further investigations should be done to study its possible etiological role.


  Associated Presentation(s):

    

No items found.


  Other Abstracts in this Sub-Category:

    

1. Impact of response to chemotherapy and treating institution on survival in primary CNS lymphoma (PCNSL): Long-term results of the multicenter BMPD study.

Meeting: 2004 ASCO Annual Meeting   Abstract No: 1522   First Author: A. Korfel
Category: Adult Leukemia, Lymphoma and Transplantation - Lymphoma

    

2. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab – early stopping after the first interim analysis.

Meeting: 2004 ASCO Annual Meeting   Abstract No: 6500   First Author: M. G. Pfreundschuh
Category: Adult Leukemia, Lymphoma and Transplantation - Lymphoma

    

3. Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL): Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).

Meeting: 2004 ASCO Annual Meeting   Abstract No: 6501   First Author: W. Hiddemann
Category: Adult Leukemia, Lymphoma and Transplantation - Lymphoma

    

More...


  Abstracts by R. Liang:

    

1. Treatment outcomes in anaplastic thyroid carcinoma from 1966-2006: Failure of overall survival enhancement despite four decades of progress in surgery, radiotherapy and chemoradiation.

Meeting: 2007 ASCO Annual Meeting   Abstract No: 16537   First Author: P. Chan
Category: Head and Neck Cancer

    

2. XELOX causes less disabling peripheral neuropathy than FOLFOX 4 for Chinese colorectal cancer patients.

Meeting: 2007 ASCO Annual Meeting   Abstract No: 14592   First Author: T. Yau
Category: Gastrointestinal (Colorectal) Cancer - Colorectal Cancer (including liver metastases)

    

3. Bevacizumab-based chemotherapy in Hong Kong Chinese patients with metastatic colorectal cancer.

Meeting: 2007 Gastrointestinal Cancers Symposium   Abstract No: 455   First Author: T. Yau Dr
Category: Colon and Rectum - Multidisciplinary Treatment

    

More...


  Presentations by R. Liang:

    

1. Helper T-lymphocyte Precursor Frequency (htlpf) Predicts The Occurrence Of Graft-versus-host Disease (gvhd) And Disease Relapse After Allogeneic Bone Marrow Transplantation

Meeting: 2001 ASCO Annual Meeting
Presenter: Raymond Liang, MD
Session: Bone Marrow Transplantation/Cytokines (Poster Discussion)

    

2. International Symposium Liver Cancer: A Global Problem

Meeting: 2000 ASCO Annual Meeting
Chair: Raymond Liang, MD
Session: International Symposium-Liver Cancer: A Global Problem

    

More...


  Educational Book Manuscripts by R. Liang:

    

No items found.




 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2009 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.